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THE IMPACT OF COPING STRATEGIES EXERCISED BY CHILDREN AND 
THEIR FAMILIES ON CLINICAL MANAGEMENT, DISEASE OUTCOME, 
AND EMOTIONAL WELL-BEING IN CHILDREN WITH NEWLY DIAGNOSED 
INFLAMMATORY BOWEL DISEASE 
DEREK COLLINS 
ABSTRACT 
 
Background: Inflammatory bowel disease (IBD) is a group of conditions characterized 
by chronic inflammation of the gastrointestinal (GI) tract. A new diagnosis of IBD in 
children and adolescents can have significant psychosocial effects on both the patient and 
the family. Child and parental coping strategies play a crucial role in the adjustment to 
IBD, especially within the first year of the diagnosis. 
 
Aims: The primary aim of the study was to assess the stability of coping measures over 
time in children and parents following a new pediatric IBD diagnosis. The study also 
aimed to assess the impact of parental coping on parental healthcare resource utilization 
for children with newly diagnosed IBD, as well as the impact of parental coping on 
anxiety, depression, and quality of life in children with newly diagnosed IBD. 
 
Methods: This was a prospective, longitudinal cohort study at Boston Children’s 
Hospital (BCH) that focused on children and adolescents with newly diagnosed IBD, as 
well as their parents. Patients and their parents were approached at the time they enrolled 
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in the study and then again about 12 months later as part of a one-year follow-up. At both 
time points, they were asked to fill out various questionnaires about psychological 
functioning and answer other questions about medical care. 
 
Results: The study identified and encountered 465 IBD patients, of which 126 were 
eligible for recruitment. There were 70 patients and families who signed a consent form 
for enrollment, 55 who fully or partially completed the questionnaires at baseline, and 
only 5 who also completed the questionnaires at follow-up. Due to the limited number of 
participants who completed the questionnaires at follow-up, no definitive conclusions 
could be drawn about the stability of coping measures over time. Parental anxiety, 
parental depression, frequent parental stress, and difficult parental stress were all found to 
be positively correlated with healthcare utilization and negatively correlated with the 
child’s quality of life. Parental anxiety, frequent parental stress, and difficult parental 
stress were all found to be positively correlated with the child’s anxiety. Parental 
depression, frequent parental stress, and difficult parental stress were all found to be 
positively correlated with the child’s depression. 
 
Conclusion: Preliminary findings suggest that poor parental coping leads to decreased 
child quality of life and increased healthcare utilization, child anxiety, and child 
depression. A larger sample size is needed to accurately evaluate the stability of coping 
measures over time. The next steps for this study involve further examination of the 
impact of parental coping and enrollment of more patients and families. 
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INTRODUCTION 
Clinical Presentation of Inflammatory Bowel Disease 
 Inflammatory bowel disease (IBD) is an umbrella term used to characterize 
disorders resulting in chronic inflammation in the gastrointestinal (GI) tract. Although its 
etiology is unclear, IBD is believed to be the result of a complex set of interactions 
between genetic, host immunity, and environmental factors (Rabizadeh & Dubinsky, 
2013). While the clinical presentation can vary from patient to patient, classic symptoms 
of IBD include abdominal pains, chronic diarrhea, rectal bleeding, weight loss, fatigue, 
and reduced appetite. However, with chronic disease activity, IBD may lead to additional 
physical manifestations such as osteopenia, skin and joint disease, growth retardation, 
and pubertal delay (Keethy, Mrakotsky, & Szigethy, 2014). 
IBD is primarily encompassed by two main subtypes: Crohn’s disease (CD) and 
ulcerative colitis (UC). The inflammation observed in patients with CD can affect any 
portion of the GI tract and most often presents in a discontinuous fashion. The 
inflammation associated with CD is often transmural can extend from the mucosa to the 
serosa. In contrast, the inflammation observed in patients with UC typically begins in the  
rectum and extends, in a contiguous fashion, to involve some or all (pan-colitis) of the 
large intestine. The inflammation in UC is limited to the mucosal surface and does not 
typically result in mural disease. These and other clinical differences between CD and 
UC are highlighted in Table 1. The terms IBD type unclassified (IBD-U) or indeterminate 
colitis (IC) refers to clinical scenarios in which the histopathological and clinical features 
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do not permit a reliable distinction between diagnoses of CD and UC (Kapoor, Bhatia, & 
Sibal, 2016; Quach, Nguyen, & Benchimol, 2013). 
 
Table 1. Clinical Differences Between Crohn’s Disease and Ulcerative Colitisa 
 
aTaken from (Kapoor, Bhatia, & Sibal, 2016) 
Diagnosis of Inflammatory Bowel Disease 
 The diagnosis of IBD relies on a combination of clinical history, serologic and 
stool studies, endoscopic evaluation, and radiologic imaging (Malmborg & Hildebrand, 
2015). Common laboratory abnormalities observed in children with IBD at diagnosis 
include anemia, thrombocytosis, hypoalbuminemia, and elevated levels of inflammatory 
markers. Stool cultures are used to exclude infections as a cause for symptoms, and 
noninvasive stool markers including fecal calprotectin (CPT) and lactoferrin (FLA) are 
useful markers of small and large bowel inflammation in pediatric and adult patients with 
IBD. There is a growing literature discussing the use of immunologic markers for 
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diagnosing and assessing patients with IBD. Commercial assays currently exist to assess 
levels of both Saccharomyces cerevisiae antibodies (ASCA) and perinuclear anti-
neutrophil cytoplasmic antibodies (p-ANCA) in an effort to help differentiate patients 
with CD from those with UC. Elevated ASCA levels are highly predictive of CD, 
whereas elevated serum p-ANCA levels are detected in the serum of 60%-70% of 
patients with UC. 
 Endoscopic evaluation, and specifically upper endoscopic (EGD) and ileo-
colonoscopy, remain the gold standard for the diagnosis and classification of IBD in 
children and adults. Gross and histopathologic findings are crucial for determining 
disease severity and extent and for distinguishing UC from CD. Even if inflammation 
identified in the upper GI tract is acute or histologically nonspecific, it can provide added 
information in patients with indeterminate disease. To maximize yield, biopsies are 
obtained from macroscopically involved and non-involved tissue in both the upper and 
lower GI tract. In addition, video capsule endoscopy may be used to evaluate the mid and 
distal small intestine when a high suspicion for CD present in portions of the intestines 
not readily accessible using standard endoscopic techniques.    
 Small-bowel imaging is essential for mapping disease location, assessing severity, 
and identifying complications such as fistulas, abscesses, and intestinal strictures. 
Historically, the fluoroscopic upper GI study with small bowel follow-through (SBFT) 
examination has been the radiological technique of choice. SBFT is best at demonstrating 
mucosal disease, but is two-dimensional and poorly visualizes extra-luminal disease.  
Cross-sectional imaging, including magnetic resonance imaging (MRI) and/or computer-
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assisted tomography (CT) is now much more likely to be requested. CT scans are the 
quickest to perform and have the greatest technical resolution, but they carry the highest 
risk of ionizing radiation exposure. In contrast, MRI is costly, time consuming, and more 
useful when soft tissue characterization is required (Kapoor, Bhatia, & Sibal, 2016; 
Rabizadeh & Dubinsky, 2013; Rosen, Dhawan, & Saeed, 2015). Both CT and MRI 
studies have the advantage of providing 3-D representations to clinicians and surgeons. 
However, MRI does not rely on the use of ionizing radiation to image the abdomen and 
pelvis, unlike conventional CT and fluoroscopic studies. 
Treatment of Inflammatory Bowel Disease 
 Treatment of pediatric patients with IBD is focused on the individual, determined 
by disease location and severity, and approached with consideration of many other 
factors. Although initial IBD therapies were mechanistically limited, consisting primarily 
of sulfasalazine and corticosteroid therapy, newer advances in pharmacologic therapy 
have resulted in a tiered response to IBD treatment. While the initial goal of symptom 
resolution and improved quality of life has not changed, the availability of more potent 
and disease-specific therapies now permits consideration of mucosal and histologic 
remission as well as modifying the natural history of the disease as valid research study 
and clinical endpoints. Thus, the current goals of IBD treatment in children are now more 
numerous and have been broadened to include mucosal healing, symptom control, 
increased quality of life, restoration of normal growth, prevention of surgical 
complications and pubertal delay, minimization of medication side effects and toxicity, 
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and long-lasting disease remission (Kapoor, Bhatia, & Sibal, 2016; Malmborg & 
Hildebrand, 2015; Rabizadeh & Dubinsky, 2013; Rosen, Dhawan, & Saeed, 2015). 
There are some important differences between the treatment of IBD in children 
and adults. Therapies approved specifically for children with IBD are lacking, and most 
of the treatment regimens in current practice have been extrapolated from adult studies 
(Malmborg & Hildebrand, 2015; Rabizadeh & Dubinsky, 2013). Treatment for children 
with IBD, much like their adult counterparts, often follows a “step-up” approach, in 
which medications with milder toxicity are used as first-line therapy before moving on to 
more aggressive therapies with higher toxicity if necessary (Kapoor, Bhatia, & Sibal, 
2016). Clinicians use the pediatric ulcerative colitis activity index (PUCAI) and the 
pediatric Crohn disease activity index (PCDAI) to assess disease activity in UC and CD, 
respectively. These two validated scores include illness measures in three domains that 
are collected routinely as part of the medical visit: self-reports of pain and functional 
disability, clinician-rated severity, and objective data, such as blood tests, weight, and 
growth charting (Jones et. al, 2011; Kapoor, Bhatia, & Sibal, 2016). 
Treatment of pediatric patients with IBD can be divided into several different 
categories or stages: disease remission, induction, and maintenance of therapy. While 
some therapies are effective for both induction and maintenance of remission for both CD 
and UC, others are more disease and geographically specific. 5-Aminosalicylic acid (5-
ASA) compounds exert a topical anti-inflammatory effect on the intestinal mucosa and 
are recommended for both induction and maintenance in pediatric UC patients with mild 
to moderate disease activity. Corticosteroids are effective for induction in pediatric 
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patients with CD and UC, but they are inappropriate for maintenance due to the many 
side effects associated with long-term use, such as growth retardation, acne, and moon 
face. 
Exclusive enteral nutrition (EEN) is often suggested as a first choice of therapy to 
induce remission in children with CD, due to its ability to heal mucosal inflammation, 
while at the same time correct nutritional deficiencies, promote ponderal and linear 
growth, and avoid steroid-associated adverse effects. Anti-tumor necrosis factor (TNF) 
agents, which are therapeutic monoclonal antibodies designed to neutralize 
proinflammatory cytokines in patients with IBD, are typically used in children with 
moderate to severe IBD refractory to corticosteroids. Immunomodulators such as 
azathioprine, mercaptopurine, and methotrexate are mainly effective as adjunct or 
maintenance therapies. Finally, surgery is considered in children who fail medical 
therapy or suffer from complications of IBD including growth retardation, delayed 
pubertal development, and bowel stricture or perforation (Malmborg & Hildebrand, 2015; 
Rabizadeh & Dubinsky, 2013; Rosen, Dhawan, & Saeed, 2015). 
Inflammatory Bowel Disease in Children and Adolescents 
Studies have concluded that approximately 25% of all patients with IBD are 
diagnosed prior to turning 20 years of age. Among children with IBD, 4% present before 
the age of 5 and 18% before the age of 10, with a peak onset in adolescence. 
Furthermore, the occurrence of IBD in children is rising, with an incidence that has risen 
to approximately 10 per 100,000 children annually. With a prevalence of 100 to 200 per 
100,000 children in the United States, or an estimated 70,000 children in total, virtually 
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all pediatricians will treat children with IBD in their primary care practices (Rosen, 
Dhawan, & Saeed, 2015).  
Although adults and children with IBD may present with similar clinical features, 
children can develop unique complications such as growth failure and pubertal delay. As 
a result, clinicians caring for children and adolescents with IBD must not only treat the 
underlying disease and its complications but also monitor changes in linear growth, 
skeletal development, and puberty (Higuchi & Bousvaros, 2017). On top of the stress of 
an IBD diagnosis, the potential for additional difficulties and heightened disease severity 
can lead to children and their families feeling overwhelmed. Thus, effective management 
of IBD in the child or adolescent demands a holistic model of care, with recognition of 
the many wider effects on the individual and their family (Bishop, Lemberg, & Day, 
2014). 
The rising incidence, unique complications, and emotional strain associated with 
the diagnosis and therapy have made gaining a better understanding of pediatric IBD an 
area of particular clinical interest (Keethy, Mrakotsky, & Szigethy, 2014).  
Child and Parent Psychosocial Burden of Inflammatory Bowel Disease  
The effects of IBD in childhood and adolescence extend far beyond the physical 
manifestations of the disease (Bishop, Lemberg, & Day, 2014). Compared with other 
chronic illnesses, such as diabetes and chronic headaches, IBD may be especially difficult 
for patients to adapt to because of apparent symptoms (flatulence, diarrhea, delayed 
puberty) and treatment side effects (acne, moon facies, moodiness) that are socially 
embarrassing and difficult to discuss. The successful completion of normal psychosocial 
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and developmental tasks can be especially challenging. The process of adolescent 
transition from family dependence to close peer friendships may also be delayed 
(MacPhee, Hoffenberg, & Feranchak, 1998). Having IBD during adolescence, a critical 
period of physical, psychological, and social development, can be especially demanding 
and may have significant adverse effects on the normal developmental patterns of self-
esteem and socialization (Lindfred et. al, 2008). Studies have demonstrated that anxiety 
and depression are more common in patients with IBD than in otherwise healthy aged-
matched peers (McCombie, Mulder, & Gearry, 2015). 
Complications associated with the diagnosis and management of IBD in 
childhood also have a significant impact on parents as well. In some cases, parents may 
have more psychosocial adjustment difficulties than their chronically ill children 
(MacPhee, Hoffenberg, & Feranchak, 1998). The presence of a chronic condition in 
children places the well-being of the entire family at risk, as the burden of care increases 
vulnerability to major psychological and social disturbances (Jackson et al., 2015). From 
the moment of diagnosis, parents are pushed into a world that requires them to adapt their 
expectations as well as gather information and make decisions in an area that is 
completely new and unknown to them. In addition, other members of the family must 
also adapt to the complex challenges that the chronic disease brings with it (Ljubica et al., 
2013). There are multiple milestones, each presenting with discrete concerns, including 
diagnosis, initiation of treatment, maintenance visits, and the uncertainties related to if 
and when clinical relapse may occur (Jackson et al., 2015).  
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Stressful life events and lack of family cohesion are predictive of child and 
adolescent depression in new-onset IBD. For this reason, it is necessary to consider 
individual and family factors when examining the potential adjustment, or 
maladjustment, to IBD. Chronic illnesses like IBD test the range of operant coping skills 
in both children and the parents, especially in the first year post-diagnosis (MacPhee, 
Hoffenberg, & Feranchak, 1998). Coping may be broadly defined as “cognitive and 
behavioral efforts to manage specific external or internal demands (and conflicts between 
them) that are appraised as taxing or exceeding the resources of a person”. Coping 
strategies may contribute to either impaired or improved health-related quality of life 
(HRQOL), anxiety, and depression (McCombie, Mulder, & Gearry, 2015). Moreover, the 
child’s adjustment to the illness and to the model of the parent’s response is likely to 
affect compliance and the perception of disease severity (MacPhee, Hoffenberg, & 
Feranchak, 1998). 
There has been a range of approaches employed by clinicians and investigators to 
attempt to classify coping styles in patients with IBD. In most cases, these coping 
strategies are divided into problem-focused vs. emotion-focused coping, and adaptive vs. 
maladaptive coping. Problem-focused coping aims to alter or eliminate the source of 
stress, whereas emotion-focused coping aims to reduce or nullify the emotional distress 
caused by the situation. Adaptive coping leads to the reduction or overall elimination of 
distress; the problem (i.e. IBD symptoms) may still be present, but emotional, social, or 
physiological distress has been reduced. Conversely, maladaptive coping includes 
strategies that increase such distress (McCombie, Mulder, & Gearry, 2015). It has been 
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theorized that maladaptive parental coping strategies, such as being overprotective, 
fearing premature death of their child, and reducing expectations from their child, 
negatively affect the child’s physical, emotional, and social development (Ljubica et al., 
2013). 
While there have been many cross-sectional studies of coping in patients with 
IBD, prospective longitudinal studies are lacking. Therefore, little is known about the 
stability of coping strategies and how their relationships with physical and mental 
outcomes change over time (McCombie, Mulder, & Gearry, 2015). This study further 
assesses how child and parent coping strategies impact clinical management, disease 
outcome, and emotional well-being over time in pediatric patients with newly diagnosed 
IBD. The information collected in this study will be used to identify patients and families 
most in need of assistance and serve as a basis to develop appropriate medical 
psychosocial supports to meet their needs. In the long run, the goal of this study is to 
contribute to improvements in overall quality of care and to reduce overall medical 
utilization.
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SPECIFIC AIMS 
 
The primary aims of this study are the following: 
• To assess the stability of coping measures over time in children and parents 
following a new pediatric IBD diagnosis 
• To assess the impact of parental coping on parental healthcare resource utilization 
for children with newly diagnosed IBD 
• To assess the impact of parental coping on anxiety, depression, and quality of life 
in children with newly diagnosed IBD 
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METHODS 
Study Design 
The IBD Coping Project is a prospective, longitudinal cohort study being 
conducted in the Center for Inflammatory Bowel Disease at Boston Children’s Hospital 
(BCH) (Boston, MA, USA) that focuses on gaining a better understanding of the coping 
strategies employed by children and their parents when faced with the challenges of a 
new diagnosis of IBD. Patients and their parents are surveyed at the time of enrollment 
and then again about 12 months later as part of a one-year follow-up. At both time points, 
patients and parents are asked to fill out previously validated questionnaires that address 
psychological functioning and general attitudes about medical care. The questionnaires 
administered at the one-year follow-up are identical to those completed at the time of 
enrollment.  
The study is designed to learn more about how children and families cope with a 
new diagnosis of IBD. We hypothesize that a better understanding of how families cope 
with chronic gastrointestinal illness will contribute to the development of improved 
psychosocial supports for high-risk child/parent dyads. For example, data collected in this 
preliminary study could be used to develop therapies and programs aimed at supporting 
families with a child with a new chronic diagnosis such as IBD.  
Participation is voluntary for patients and parents and is uncompensated. Patients 
are allowed to stop the surveys altogether or withdraw from the study at any time without 
incurring any consequence. Furthermore, subjects are not required to answer any 
questions that they do not wish to answer or do not know how to answer. They may come 
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across questions that frustrate them, make them uncomfortable, or cause them to 
remember situations that were upsetting to them. If any of these situations arise, the 
research team offers to have them speak to someone about how they are feeling. 
Strict subject confidentiality is another important component of the study design. 
Each administered questionnaire is coded by number and does not contain personally 
identifiable information. Moreover, the information in the questionnaires does not 
become part of the patient’s medical record. The only circumstance in which 
confidentiality cannot be assured is if during the family’s participation in this research, 
there is a reason to believe that the patient or parent is at risk for being suicidal or 
otherwise harming themselves or others. In that case, the research team will act on this 
suspicion and disclose the information to the appropriate individuals in an effort to get 
the at-risk party the help and support that they require. Although confidentiality cannot be 
guaranteed if this were to occur, the research team would inform the family that they plan 
to disclose this information because they feel it is best for their safety. 
The IBD Coping Project is designed to enroll 50-70 IBD patients and families 
from Boston Children’s Hospital. The study was approved by the Institutional Review 
Board (IRB) at Boston Children’s Hospital (Protocol Number: P0023915) with 
Continuing Review approved on September 23, 2018, extending study activity to 
September 24, 2019. 
The methods described in the subsequent sections relate directly to information 
gathered in the IBD Coping Project from January 1, 2017 to April 1, 2019 and used in the 
development of this thesis study. 
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Participant Selection and Enrollment 
 Patient selection was determined primarily through the use of hospital electronic 
medical records. Members of the research team reviewed GI pathology reports, the daily 
IBD inpatient list, IBD ambulatory visit records, and GI provider referrals at BCH and its 
satellite locations. Those who were eligible for the study were between the ages of 9 and 
17 and were diagnosed with IBD within the previous 6 months. In addition, eligible 
patients spoke English, received their longitudinal IBD care at BCH, and had no changes 
in their psychotropic medications in the previous 6 months. 
Before approaching patients and their parents for their enrollment in the study, the 
research team first contacted the patient’s primary GI provider. The research team 
expressed their interest in recruiting the patient to the study and asked the GI provider 
whether the patient was a good fit for their research. If permission was granted, a member 
of the research team approached the patient and parent(s) for recruitment to the study. 
Though typically completed in person when the child/adolescent was in the hospital as an 
inpatient or in the clinic as an outpatient, this was also done online through email. During 
this initial approach, the member of the research team introduced the study, explained 
what involvement in the study entailed, and, if the patient and parent(s) were interested in 
participating, distributed the consent form and the respective questionnaires. The patient 
and family were officially enrolled in the study when the consent form (Figure 1) was 
signed and dated by the parent, child/adolescent, and research investigator or associate. 
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Figure 1. An example of the BCH IBD Coping Project Research Consent Form. 
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Figure 1. An example of the BCH IBD Coping Project Research Consent Form. 
(Continued) 
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Figure 1. An example of the BCH IBD Coping Project Research Consent Form. 
(Continued) 
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Figure 1. An example of the BCH IBD Coping Project Research Consent Form. 
(Continued) 
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Figure 1. An example of the BCH IBD Coping Project Research Consent Form. 
(Continued) 
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Figure 1. An example of the BCH IBD Coping Project Research Consent Form. 
(Continued) 
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Figure 1. An example of the BCH IBD Coping Project Research Consent Form. 
(Continued) 
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Figure 1. An example of the BCH IBD Coping Project Research Consent Form. 
(Continued) 
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Figure 1. An example of the BCH IBD Coping Project Research Consent Form. 
(Continued) 
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Study Measures 
 The study metrics collected measures of anxiety, depression, and quality of life 
through established questionnaires. These forms were completed by the patient at the 
time of enrollment (baseline) and again about 12 months later (follow-up). 
 
1. The Children’s Depression Inventory (CDI; Kovacs, 1992) is a 27-item, self-
rated, symptom-oriented assessment that rates the severity of symptoms related to 
depression or dysthymic disorder in children and adolescents (Figure 2). Each 
item consists of three statements, and each statement corresponds to a rating of 0, 
1, or 2, with the selected statement best describing the individual’s feelings and 
ideas in the past two weeks. Raw scores can range from 0-54, which are then 
converted to standardized T-scores based on age and gender. The 27 items are 
also grouped into five major factor areas: Negative Mood, Interpersonal 
Problems, Ineffectiveness, Anhedonia, and Negative Self-Esteem. Negative Mood 
reflects feeling sad, feeling like crying, worrying about “bad things,” being 
bothered or upset by things, and being unable to make up one’s mind. 
Interpersonal Problems reflects problems and difficulties in interactions with 
people, including trouble getting along with people, social avoidance, and social 
isolation. Ineffectiveness reflects a negative evaluation of one’s ability and school 
performance. Anhedonia reflects impaired ability to experience pleasure. 
Individuals scoring high on this scale may suffer from loss of energy and 
problems with sleeping and appetite. Negative Self-Esteem reflects low self-
 25 
esteem, self-dislike, and feelings of being unloved. Statistical reliability and 
validity of the CDI have been established (Saylor et al., 1984). 
 
2. The Screen for Child Anxiety Related Emotional Disorders (SCARED, Child 
Version; Birmaher et al., 1999) is a self-report screening questionnaire for 
anxiety disorders in children and adolescents (Figure 3). It consists of 41 items 
that measure the frequency or intensity of a variety of symptoms or behaviors. 
Each item lists a sentence that describes how people feel and asks the individual 
to select the answer choice that seems to describe him or her for the last three 
months. The individual has three possible answer choices for each item: “Not 
True or Hardly Ever True,” “Somewhat True or Sometimes True,” or “Very True 
or Often True,” which correspond to ratings of 0, 1, or 2, respectively. The 
SCARED encompasses several Diagnostic and Statistical Manual of Mental 
Disorders (DSM)-IV categorizations of anxiety disorders and can discriminate 
among distinct anxiety disorders. This measure screens specifically for 
generalized anxiety disorder, separation anxiety disorder, social anxiety disorder, 
significant school avoidance, and panic disorder or significant somatic symptoms. 
The assessment has been found to be both valid and reliable in research settings. 
 
3. The IMPACT-III Questionnaire (Otley et al., 2002, 2006) is a HRQOL 
questionnaire for children with IBD (Figure 4). It consists of 35 questions that ask 
about the child’s life with IBD, from pains the child may suffer to feelings or 
 26 
worries the child may have. Each question has five possible answer choices that 
are rated on a 5-point scale, with the first answer choice corresponding to a rating 
of 5 and the fifth answer choice corresponding to a rating of 1. The child is asked 
to select the one that best fits his or her answer. The 35 questions are also grouped 
into six HRQOL domain scales: Body Image, Treatments and Interventions, 
Bowel Symptoms, Social Functioning, Emotional Functioning, and Systemic 
Symptoms. Statistical reliability, specifically test-retest reliability, and validity are 
strongly evident. 
 
4. The Patient Health Questionnaire-9 (PHQ-9; Kroenke, Spitzer, & Williams, 
2001) is a 9-question instrument given to patients in a primary care setting to 
screen for the presence and severity of depression (Figure 5). The questions are 
based on diagnostic criteria of depression from the DSM-IV and ask about 
problems that people can experience. Each question lists one of those problems 
and asks the individual how often he or she has been bothered by the problem 
over the last two weeks. The individual has four possible answer choices for each 
question: “Not at all,” “Several days,” “More than half the days,” or “Nearly 
every day,” which correspond to ratings of 0, 1, 2, or 3, respectively. A tenth 
question, which is not factored into the final score, asks how difficult the 
problems make it for the individual to do work, take care of things at home, or get 
along with other people. Validity was ascertained in research incorporating 
primary care and obstetric clinics. 
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Figure 2. An example of the Children’s Depression Inventory (CDI). Taken from 
(Kovacs, 1992). 
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Figure 2. An example of the Children’s Depression Inventory (CDI). (Continued) 
 29 
 
Figure 3. An example of the Screen for Child Anxiety Related Emotional Disorders 
(SCARED). Taken from (Birmaher et al., 1999). 
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Figure 3. An example of the Screen for Child Anxiety Related Emotional Disorders 
(SCARED). (Continued) 
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Figure 4. An example of the IMPACT-III Questionnaire. Taken from (Otley et al., 
2002, 2006). 
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Figure 4. An example of the IMPACT-III Questionnaire. (Continued) 
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Figure 4. An example of the IMPACT-III Questionnaire. (Continued) 
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Figure 4. An example of the IMPACT-III Questionnaire. (Continued) 
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Figure 4. An example of the IMPACT-III Questionnaire. (Continued) 
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Figure 4. An example of the IMPACT-III Questionnaire. (Continued) 
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Figure 4. An example of the IMPACT-III Questionnaire. (Continued) 
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Figure 5. An example of the Patient Health Questionnaire-9 (PHQ-9). Taken from 
(Kroenke, Spitzer, & Williams, 2001). 
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 For parents, the study collected data with respect to coping, anxiety, and 
depression through established questionnaires. Either the patient’s mother, father, or legal 
guardian completed these questionnaires at the time of enrollment (baseline) and again 
about 12 months later (follow-up). 
 
1. The Healthcare Utilization Survey is a 6-item assessment that measures the 
frequency of common parental and family actions with respect to their child’s 
IBD treatment and disease maintenance (Figure 6). For each item, the parent is 
asked to best estimate how many times in the last month did the family perform 
the particular action listed. The items, which are open-ended to prompt a 
numerical or not applicable response, address office visits, phone calls, trips to the 
emergency room (ER), and hospitalizations. 
 
 
Figure 6. An example of the Healthcare Utilization Survey. Taken from (Zimmerman, 
2017). 
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2. The Pediatric Inventory for Parents (PIP; Streisand, Braniecki, Tercyak, & 
Kazak, 2001) is a 42-item self-report instrument that measures childhood illness-
related parenting stress (Figure 7). Each item lists a medically-related situation or 
thought that is considered stressful to parents of children with a serious illness. 
Each item has two associated answer columns: frequency and difficulty. The 
frequency column asks how often the event has occurred in the past 7 days and 
has five possible answer choices: “Never” (which corresponds to a rating of 1), 
“Rarely” (2), “Sometimes” (3), “Often” (4), and “Very often” (5). The difficulty 
column asks how difficult the event was or generally is and also uses the five-
point rating scale: “Not at all” (1), “A little” (2), “Somewhat” (3), “Very much” 
(4), and “Extremely” (5). The 42 items are also grouped into four domains: 
Communication, Emotional Distress, Medical Care, and Role Function. Excellent 
reliability and validity were determined for this measure in pediatric IBD in recent 
years (Gray et al., 2013). 
 
3. The Hospital Anxiety and Depression Scale (HADS; Zigmond & Snaith, 1983) 
is a questionnaire used to determine the levels of anxiety and depression that a 
person is experiencing (Figure 8). It consists of 14 items of which 7 relate to 
anxiety and 7 relate to depression. Each item has four answer choices that 
correspond to a rating of 0, 1, 2, or 3. The participant is asked to immediately 
choose the reply that is closest to how he or she has been feeling in the past week. 
This valid and reliable measure can be administered any number of times to 
assess emotional stability in parents (Snaith, 2003). 
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Figure 7. An example of the Pediatric Inventory for Parents (PIP). Taken from 
(Streisand et al., 2001). 
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Figure 7. An example of the Pediatric Inventory for Parents (PIP). (Continued) 
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Figure 8. An example of the Hospital Anxiety and Depression Scale (HADS). Taken 
from (Zigmond & Snaith, 1983). 
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Data Collection 
Relevant clinical information from enrolled patients was abstracted from 
PowerChart (Cerner Corporation, North Kansas City, MO, USA), the electronic medical 
record used on the internal BCH network. The acquired data were stored in Microsoft 
Word and Excel documents (Microsoft Corporation, Redmond, WA, USA) in a 
password-protected server at BCH. For patients who were not enrolled in the study, the 
data collected included age, IBD classification, date of IBD diagnosis, GI provider, 
appointment dates, and reasons for ineligibility, if applicable.  
For patients enrolled in the study, after the consent form (Figure 1) was signed 
and dated by all required parties, the Research Study Coordinator distributed the 
questionnaires (Figures 2-8) to the patient and parent(s). This was done either in person 
(typically in an inpatient, ambulatory, or medical infusion setting) or online by email. If 
distributed in person, the questionnaires were either completed in real time or the metrics 
could be completed on-line. Subjects who chose on-line completion were sent an email to 
a digital link that allowed them to complete and submit the questionnaires electronically 
through Research Electronic Data Capture (REDCap), a Health Insurance Portability and 
Accountability Act (HIPAA)-compliant application. 
Patients and their parents were instructed to answer as many items as possible and 
to clearly indicate items that they chose not to answer, if any. If completing the 
questionnaires on paper, the participant made such an indication by crossing out the 
question. If completing the questionnaires electronically, each item had an “I choose not 
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to answer” option that could be selected. All completed consent forms and questionnaires 
were stored in a locked location in the Center for Inflammatory Bowel Disease at BCH. 
The study team also obtained medical data, both at baseline and follow-up. 
Baseline measures included pertinent demographic information, date of IBD diagnosis, 
physician global assessment of disease activity, and disease extent, phenotype, and 
severity. Follow-up measures included steroid treatments, surgical procedures, the 
number of hospitalizations, IBD flares, clinic and ER visits, and phone calls to providers. 
Several measures, such as PUCAI and PCDAI scores, laboratory results (ESR, CRP, and 
HCT), stool study biomarkers (FLA and CPT), and IBD medications, were collected both 
at baseline and during follow-up. 
Enrolled patients were assigned a unique study identification number 
(BCOPE001, BCOPE002, BCOPE003, etc.) that was attached to their questionnaire 
responses and medical data to ensure patient confidentiality. After this assignment was 
made, the questionnaire responses and medical data were transferred and entered into 
REDCap, a secure, web-based application designed to support data capture for research 
studies (Harris et al., 2008). For each study participant, REDCap created a user-friendly, 
web-based Case Report Form (CRF) that compiled the patient’s data in order to facilitate 
analysis and interpretation of results. The CRF subsections included demographic 
information and baseline IBD measures (Figure 9), responses to all 7 questionnaires, and 
follow-up disease outcome measures (Figure 10). 
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Figure 9. An example of the IBD Coping Demographics Case Report Form (CRF) 
from REDCap. Available relevant baseline demographic information is collected on all 
enrolled patients. 
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Figure 9. An example of the IBD Coping Demographics Case Report Form (CRF) 
from REDCap. (Continued) 
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Figure 10. An example of the IBD Coping Outcome Measures Case Report Form 
(CRF) from REDCap. Available follow-up information including disease outcome 
measures is collected on all enrolled patients. 
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Figure 10. An example of the IBD Coping Outcome Measures Case Report Form 
(CRF) from REDCap. (Continued)  
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RESULTS 
Patient Population 
 As of March 26, 2019, 465 patients with IBD were screened. 126 were eligible 
and 339 were ineligible as determined by the aforementioned selection criteria (Figure 
11). A total of 70 patients signed a consent form for enrollment in the study. The 
remaining 56 eligible patients were further subdivided into those who were yet to be 
approached for enrollment (Pending Update), those who were approached but decided not 
to participate in the study (Patient/Family Declined), and those who were eligible but 
were not approached because their primary GI provider did not think they were a good fit 
for the study (GI Provider Declined). 
55 of the 70 consented patients partially or fully completed the baseline study 
questionnaires (Figure 11). To date, only 5 patients had completed the questionnaires at 
one-year follow-up (1YFU Yes). 32 patients had not yet had a year pass since their date 
of consent and therefore had not yet been contacted for their follow-up (1YFU Awaiting). 
The other 18 had a year pass since their date of consent, but for various reasons had not 
completed their follow-up questionnaires (1YFU No). For example, some patients were 
no longer interested in participating in the study and voluntarily withdrew. Others were 
“lost to follow-up”, defined as an enrolled patient that could not be reached after multiple 
attempts were made to contact them. Finally, one was categorized as “unresponsive”, and 
this was defined as a patient/family that chose not to respond to prompts to complete 
relevant study materials. 
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There were 15 consented patients and families who had not completed their 
baseline questionnaires. Voluntary withdrawal, loss to follow up, and unresponsiveness 
largely explain the absence of these questionnaires as well. In addition, there were 3 
patients who had completed their one-year follow-up questionnaires, but whose baseline 
questionnaire responses were lost (1YFU Complete). 
Because of the specific inclusion criteria, about three-quarters of screened patients 
were determined to be ineligible for participation in the study. The most common reason 
for ineligibility was that the patient had been diagnosed with IBD more than 6 months 
ago. The age restrictions of being younger than 9 years old or older than 17 years old also 
accounted for many of the ineligible patients. Over one-quarter of ineligible patients met 
more than one exclusion criteria. A much smaller contingent was deemed ineligible for 
being non-English speaking or primarily followed outside BCH (Other). 
Table 2 provides demographic information on the population of patients enrolled 
in the study. The gender distribution was relatively even, with males (39) being slightly 
more represented than females (31). In terms of disease classification, CD predominated 
(41), followed by UC (28) and IC (1). On average, study patients were about 14 years old 
and 2 months post-diagnosis at the time of enrollment. It should be noted that one female 
patient was inadvertently enrolled after her 18th birthday and therefore had to be 
withdrawn from the study. In addition, one male patient signed his consent form 7 
months after he had been diagnosed with IBD. However, because he and his family had 
communicated their intention to participate in the study well prior to that, the research 
team decided to keep this particular patient enrolled in the study. 
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Figure 11. Flow Diagram for BCH IBD Coping Project. This figure provides a 
breakdown of the total number of patients assessed for study participation, based on 
eligibility, enrollment status, completion of baseline questionnaires, and completion of 
one-year follow-up questionnaires. The reasons for ineligibility and incompletion of 
consent form, baseline questionnaires, and one-year follow-up questionnaires are also 
given. 1YFU = 1-year follow-up; GI = gastrointestinal; n = number of IBD patients. 
 
 
 
 
Total	Assessed(n	=	465)
Ineligible(n	=	339)
Diagnosis	>6	Months	Ago(n	=	151)
Age	<9	or	>17(n	=	75)	
>1	Exclusion	Criteria(n	=	97)
Other(n	=	16)
Eligible(n	=	126)
Consented(n	=	70)
Initial	Encounter	Attempted(n	=	15)
1YFU	Complete(n	=	3)
Withdrew(n	=	2)
Loss	to	Follow-Up(n	=	7)
Unresponsive(n	=	3)
Initial	Encounter	Complete(n	=	55)
1YFU	No(n	=	18)
Withdrew(n	=	2)
Loss	to	Follow-Up(n	=	13)
Unresponsive(n	=	3)
1YFU	Awaiting(n	=	32) 1YFU	Yes(n	=	5)
Not	Consented(n	=	56)
Pending	Update(n	=	46)
Patient/Family	Declined(n	=	5)
GI	Provider	Declined(n	=	5)
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Table 2. Enrolled Patient Population at Baselinea 
Characteristics Classification Outcome 
Patient Diagnosis IBD 70 
 CD 41 
 UC 28 
 IC 1 
Gender Male 39 
 Female 31 
 Male CD 23 
 Male UC 15 
 Male IC 1 
 Female CD 18 
 Female UC 13 
 Female IC 0 
Age in Years at Date of Consent Mean 14.50 
 Male Max 17.98 
 Male Min 9.01 
 Male Mean 14.48 
 Female Max 18.30 
 Female Min 9.44 
 Female Mean 14.51 
Time in Days from Diagnosis to Consent Mean 53.41 
 Range 1-223 
 Male Max 223 
 Male Min 1 
 Male Mean 63.13 
 Female Max 173 
 Female Min 2 
 Female Mean 41.19 
 
aThis table shows demographic information on the population of patients enrolled in the 
study. CD = Crohn’s disease; IBD = inflammatory bowel disease; IC = indeterminate 
colitis; UC = ulcerative colitis. 
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Baseline Patient Study Measures: CDI 
 52 of the 55 patients who completed their initial encounter either partially or fully 
answered the CDI assessment. Data was only included from the 48 participants who 
responded to at least 18 of the 27 items on the assessment. Raw scores were calculated 
for the CDI total score as well as for each of the 5 major factor areas. Each raw score was 
then converted to a standardized T-score for further analysis. 
Data in Table 3 provides the mean raw scores for the total CDI scale and each of 
the 5 major factor areas, along with their possible scoring ranges. Higher raw scores are 
positively correlated with higher standardized T-scores and greater severity of depressive 
symptoms. The data show that the mean raw scores were low across all factor areas. 
For the total and each of the 5 major factor areas, the mean standardized T-scores 
were in the range of 40-49 (Figure 12). Table 4 indicates that these scores represented a 
typical number of concerns and were considered average. Among the 5 major factor 
areas, T-scores were highest for Anhedonia and lowest for Negative Self-Esteem. 
 
Table 3. Baseline results for CDI Raw Scoresa 
Factor Area 
Mean Raw 
Score 
Lowest Possible 
Raw Score 
Average 
Raw 
Score 
Highest Possible 
Raw Score 
Total CDI 5.3 0 27 54 
Negative Mood 1.3 0 6 12 
Interpersonal 
Problems 0.2 0 4 8 
Ineffectiveness 1.0 0 4 8 
Anhedonia 2.4 0 8 16 
Negative Mood 0.5 0 5 10 
aThis table shows the mean raw scores for the total scale and each of the 5 major factor 
areas from 48 patients who answered the CDI at baseline. 
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Table 4. Interpretation of CDI Standardized T-Scoresa 
T-Score T-Score Interpretation 
<40 
Below Average Score  
(Fewer concerns than are typically reported) 
40-49 
Average Score  
(Typical number of concerns) 
50-59 
Slightly Above Average Score  
(Slightly more concerns than are typically reported) 
60-64 
Above Average Score  
(Somewhat more concerns than are typically reported) 
65-69 
Elevated Score  
(More concerns than are typically reported) 
70-90+ 
Very Elevated Score  
(Many more concerns than are typically reported) 
 
aAdapted from (Kovacs and Multi-Health Systems Staff, 2011) 
 
 
Figure 12. Baseline results for CDI depression outcomes. This figure shows the mean 
standardized T-scores for the total scale and each of the 5 major factor areas from 48 
patients who answered the CDI at baseline. 
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Baseline Patient Study Measures: SCARED 
 50 of the 55 patients who completed their initial encounter either partially or fully 
answered the SCARED questionnaire. Data from 3 patients who only completed one side 
of the questionnaire were excluded from analysis. Calculated scores include a total score 
as well as scores for each of the five distinct anxiety disorders for which the 
questionnaire specifically screens. 
Although 20 of the 47 patients reported low scores that did not suggest the 
presence of an anxiety disorder or symptoms, the remaining study participants (57% of 
the patients) met criteria for indication of at least one type of anxiety disorder. The most 
commonly indicated disorders were separation anxiety disorder by 34% of the patients 
and significant school avoidance by 23% of the patients (Figure 13). 
 
 
Figure 13. Baseline results for SCARED anxiety outcomes. This figure shows results 
from 47 patients who answered the SCARED at baseline. It displays the percentage of 
patients who indicated for each the anxiety disorders screened for on the SCARED. 
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Baseline Patient Study Measures: IMPACT-III 
 49 of the 55 patients who completed their initial encounter either partially or fully 
answered the IMPACT-III questionnaire. Data from one patient who only completed 7 of 
the 35 questions were excluded from analysis. A total IMPACT-III score was calculated 
in addition to scores for each of the 6 HRQOL domain scales. 
Data in Table 5 reports the mean scores for the total IMPACT-III scale and each 
of the 6 HRQOL domain scales, along with their respective possible scoring ranges. 
Higher scores are positively correlated with increased quality of life. The data show an 
above-average quality of life across all domain scales. 
 
Table 5. Baseline results for IMPACT-III quality of life outcomesa 
Domain 
Mean 
Score 
Lowest 
Possible Score 
Average 
Score 
Highest 
Possible Score 
Total 129.3 35 105 175 
Bowel Symptoms 23.7 7 21 35 
Treatment/Interventions 11.4 3 9 15 
Emotional Functioning 25.6 7 21 35 
Systemic Symptoms 10.2 3 9 15 
Body Image 10.7 3 9 15 
Social Functioning 47.7 12 36 60 
 
aThis table shows the mean scores for the total scale and each of the 6 HRQOL domain 
scales from 48 patients who answered the IMPACT-III questionnaire at baseline. 
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Baseline Patient Study Measures: PHQ-9 
 47 of the 55 patients who completed their initial encounter either partially or fully 
answered the PHQ-9. Data from one patient who only completed 4 of the 9 questions was 
excluded from analysis. A total PHQ-9 score was calculated for each of the 46 patients. 
Each total score fell into one of five different categories that characterized the 
severity of the patient’s depression. Among the 46 patients that were assessed, 26 patients 
(57%) had a total score between 0 and 4, indicating minimal depression. 14 patients 
(30%) scored between 5 and 9, indicating mild depression, and 6 patients (13%) scored 
between 10 and 14, indicating moderate depression. No patients in Figure 14 scored 
between 15 and 19 (moderately severe depression) or 20 and 27 (severe depression). The 
mean total score of the 46 patients was 4.39. 
 
 
Figure 14. Baseline results for PHQ-9 depression classifications. This figure shows 
results from 46 patients who answered the PHQ-9 at baseline. It shows the percentage of 
patients in each group of depression severity according to their total score on the PHQ-9. 
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Baseline Parent Study Measures: Healthcare Utilization Survey 
51 of the 55 sets of parents who completed their initial encounter either partially 
or fully answered the Health Utilization Survey. Data were included from all usable 
responses to each item of the survey. In total, each of the first 3 items had 47 usable 
responses, while each of the last 3 items had 46. Additionally, the total utilization number 
was calculated for each of the 46 sets of parents who provided a usable response to at 
least 3 of the survey’s 6 items. 
On average, phone calls with the child’s pediatrician and GI doctor were the most 
frequent utilization, whereas emergency room visits and inpatient hospitalizations were 
the least frequent (Figure 15). 
 
 
Figure 15. Baseline results for Healthcare Utilization Survey. This figure shows the 
mean number of parental healthcare utilization instances per month for each of the 6 
items on the Healthcare Utilization Survey. Baseline data was collected from 51 parents. 
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Baseline Parent Study Measures: PIP 
 52 of the 55 sets of parents who completed their initial encounter either partially 
or fully answered the PIP instrument. Data were included from all participants who 
responded to at least 28 of the 42 items in the Frequency or Difficulty columns on the 
instrument. In total, the Frequency column contains data from 47 participants, while the 
Difficulty column contains data from 43. Frequency and difficulty scores were calculated 
for each of the four domains along with total frequency and difficulty scores. 
Table 6 displays the mean frequency and difficulty scores for the total PIP 
instrument and each of the 4 domains, along with their respective possible scoring ranges. 
Higher scores are positively correlated with increased stress. The data show that the mean 
frequency and difficulty scores were below average in total and across all 4 domains. The 
mean frequency score also tended to be greater than the mean difficulty score, with the 
exception of the emotional distress domain. 
 
Table 6. Baseline results for PIP parental stress outcomesa 
Domain 
Mean 
Frequency 
Score 
Mean 
Difficulty 
Score 
Lowest 
Possible F/D 
Score 
Average F/D 
Score 
Highest 
Possible F/D 
Score 
Communication 21.4 16.9 9 27 45 
Emotional 
Distress 37.7 39.5 15 45 75 
Medical Care 20.5 17.1 8 24 40 
Role Function 20.4 19.4 10 30 50 
Total 100.1 93.0 42 126 210 
 
aThis table shows the mean frequency and difficulty scores for the total scale and each of 
the 4 domain scales from 47 sets of parents who answered the PIP at baseline. 
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Baseline Parent Study Measures: HADS 
51 of the 55 sets of parents who completed their initial encounter either partially 
or fully answered the HADS. Data were included from all 51 of these patient/parent 
dyads. Total scores for anxiety and depression were calculated for each set of parents.  
The mean total anxiety score (6.87) was higher than the mean total depression 
score (4.00) for parents of enrolled study participants (Figure 16). In addition, total scores 
for anxiety and depression fell into one of three different categories that characterized its 
severity. Among the 51 sets of parents who were assessed, 28 had a total anxiety score 
between 0 and 7, which was characterized as “normal.” 11 sets of parents had a total 
anxiety score between 8 and 10 (“borderline abnormal”), and the remaining 12 sets of 
parents had a total anxiety score between 10 and 21 (“abnormal”) (Figure 17). 
Although the scales for characterizing depression were identical to those of 
anxiety, the results were noticeably different. 43 sets of parents were characterized as 
“normal,” 2 sets as “borderline abnormal,” and 6 sets as “abnormal” (Figure 18). 
 
 
Figure 16. Baseline results for HADS anxiety and depression outcomes. This figure 
shows the mean total anxiety and depression scores from 51 sets of parents who answered 
the HADS at baseline. 
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Figure 17. Baseline results for HADS anxiety classifications. This figure shows results 
from 51 parents who answered the HADS at baseline. It shows the percentage of parents 
in each category of anxiety severity according to their total anxiety score on the HADS. 
 
 
Figure 18. Baseline results for HADS depression classifications. This figure shows 
results from 51 parents who answered the HADS at baseline. It shows the percentage of 
parents in each category of depression severity according to their total depression score 
on the HADS. 
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Stability of Coping Measures Over Time 
To date, 5 of the 55 patients and families who completed their initial encounter 
have either partially or fully completed the questionnaires at one-year follow-up. Data 
were included from all 5 patients, except in cases in which the patient/parent only 
completed the questionnaire at one of the two time points. For each questionnaire, a 
comparison between the patient’s/parent’s total scores at baseline and follow-up were 
analyzed. 
4 of the 5 patients demonstrated a decrease in their total CDI raw score over the 
course of their first year with IBD, while the other patient demonstrated an increase 
(Figure 19). 
2 patients showed a decrease in their SCARED total score over the course of their 
first year with IBD, while 2 patients showed an increase (Figure 20). Data and analysis 
were excluded from one patient who only completed one side of the questionnaire. 
All 4 patients analyzed for changes in their IMPACT-III total score demonstrated 
an increase over the course of their first year with IBD (Figure 21). Data and analysis 
were excluded from one patient who did not complete the questionnaire at baseline. 
All 3 patients analyzed for changes in their PHQ-9 total score showed a decrease 
over the course of their first year with IBD (Figure 22). Data and analysis were excluded 
from two patients who did not complete the questionnaire at baseline. 
4 of the 5 sets of parents displayed a decrease in their total number of healthcare 
utilization instances over the course of their child’s first year with IBD. The other set of 
parents displayed the same number of instances at baseline and follow-up (Figure 23). 
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All 5 sets of parents displayed a decrease in their PIP total frequency score over 
the course of their child’s first year with IBD (Figure 24). Over that same time period, 4 
of the 5 sets of parents also exhibited a decrease in their PIP total difficulty score, while 
the other set of parents saw an increase (Figure 25). 
All 5 sets of parents exhibited a decrease in their HADS total anxiety score over 
the course of their child’s first year with IBD (Figure 26). Over that same time period, 3 
of the 5 sets of parents also exhibited a decrease in their HADS total depression score. 
One set of parents saw their HADS total depression score stay the same, while another 
saw theirs increase (Figure 27). 
 
 
Figure 19. Change in Total CDI Raw Score Over First Year with IBD. This figure 
shows the change in the total CDI raw score from baseline to follow-up for all 5 patients 
who completed the CDI at both time points. 
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Figure 20. Change in SCARED Total Score Over First Year with IBD. This figure 
shows the change in the SCARED total score from baseline to follow-up for 4 patients 
who completed the SCARED at both time points. 
 
 
Figure 21. Change in IMPACT-III Total Score Over First Year with IBD. This 
figure shows the change in the IMPACT-III total score from baseline to follow-up for 4 
patients who completed the IMPACT-III questionnaire at both time points. 
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Figure 22. Change in PHQ-9 Total Score Over First Year with IBD. This figure 
shows the change in the PHQ-9 total score from baseline to follow-up for 3 patients who 
completed the PHQ-9 at both time points. 
 
 
Figure 23. Change in Healthcare Utilization Over First Year with IBD. This figure 
shows the change in total healthcare utilization instances from baseline to follow-up for 
all 5 sets of parents who completed the Healthcare Utilization Survey at both time points. 
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Figure 24. Change in PIP Total Frequency Score Over First Year with IBD. This 
figure shows the change in the PIP total frequency score from baseline to follow-up for 
all 5 sets of parents who completed the PIP at both time points. 
 
 
Figure 25. Change in PIP Total Difficulty Score Over First Year with IBD. This 
figure shows the change in the PIP total difficulty score from baseline to follow-up for all 
5 sets of parents who completed the PIP at both time points. 
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Figure 26. Change in HADS Total Anxiety Score Over First Year with IBD. This 
figure shows the change in the HADS total anxiety score from baseline to follow-up for 
all 5 sets of parents who completed the HADS at both time points. 
 
 
Figure 27. Change in HADS Total Depression Score Over First Year with IBD. This 
figure shows the change in the HADS total depression score from baseline to follow-up 
for all 5 sets of parents who completed the HADS at both time points. 
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Impact of Parental Coping on Healthcare Resource Utilization 
 The impact of parental coping on healthcare resource utilization was measured by 
examining the respective relationships between healthcare utilization and parental 
anxiety, parental depression, frequency of parental stress, and difficulty of parental stress. 
In all cases, healthcare utilization was represented by the total number of healthcare 
utilization instances that was calculated from the Healthcare Utilization Survey. 
 Parental anxiety was represented by the total anxiety score calculated from the 
HADS. Data were analyzed from 44 sets of parents who completed both the HADS and 
the Healthcare Utilization Survey. Data in Figure 28 illustrates that total healthcare 
utilization instances were positively correlated with the HADS total anxiety score. 
 Parental depression was represented by the total depression score calculated from 
the HADS. Data were analyzed from 44 sets of parents who completed both the HADS 
and the Healthcare Utilization Survey. The data in Figure 29 show that total healthcare 
utilization instances were positively correlated with the HADS total depression score. 
Frequency of parental stress was denoted by the total frequency score calculated 
from the PIP. Data were analyzed from 42 sets of parents who completed both the PIP 
and the Healthcare Utilization Survey. The data in Figure 30 show that total healthcare 
utilization instances were positively correlated with the PIP total frequency score. 
Difficulty of parental stress was denoted by the total difficulty score calculated 
from the PIP. Data were analyzed from 38 sets of parents who completed both the PIP 
and the Healthcare Utilization Survey. The data in Figure 31 show that total healthcare 
utilization instances were positively correlated with the PIP total difficulty score. 
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Figure 28. Impact of Parental Anxiety on Healthcare Utilization. This figure shows 
the relationship between the HADS total anxiety score and the total number of healthcare 
utilization instances from the Healthcare Utilization Survey. Data were analyzed from 44 
sets of parents who completed both measures. 
 
 
Figure 29. Impact of Parental Depression on Healthcare Utilization. This figure 
shows the relationship between the HADS total depression score and the total number of 
healthcare utilization instances from the Healthcare Utilization Survey. Data were 
analyzed from 44 sets of parents who completed both measures. 
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Figure 30. Impact of Frequent Parental Stress on Healthcare Utilization. This figure 
shows the relationship between the PIP total frequency score and the total number of 
healthcare utilization instances from the Healthcare Utilization Survey. Data were 
analyzed from 42 sets of parents who completed both measures. 
 
 
Figure 31. Impact of Difficult Parental Stress on Healthcare Utilization. This figure 
shows the relationship between the PIP total difficulty score and the total number of 
healthcare utilization instances from the Healthcare Utilization Survey. Data were 
analyzed from 38 sets of parents who completed both measures. 
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Impact of Parental Coping on Child Anxiety, Depression, and Quality of Life 
The impact of parental coping on child anxiety, depression, and quality of life was 
measured by examining the relationships between patient study measures and parent 
study measures. Child anxiety was represented by the total anxiety score calculated from 
the SCARED. Child depression was represented by the total depression score calculated 
from the PHQ-9 (the PHQ-9 was used instead of the CDI because its data set contained 
more questionnaires that were fully completed). Child quality of life was represented by 
the total HRQOL score calculated from the IMPACT-III questionnaire. Parental anxiety 
and depression were represented by the total anxiety and depression scores calculated 
from the HADS, respectively. Frequency and difficulty of parental stress were denoted by 
the total frequency and difficulty scores calculated from the PIP, respectively. 
Data were analyzed from 45 patients and families who completed both the HADS 
and the SCARED. The data in Figure 32 illustrates that the SCARED total anxiety score 
was positively correlated with the HADS total anxiety score. Similarly, data were 
analyzed from 44 patients and families who completed both the HADS and the PHQ-9. 
The data in Figure 33 illustrates that the PHQ-9 total depression score was positively 
correlated with the HADS total depression score. 
Data analyzed from 45 patients and families who completed both the HADS and 
the IMPACT-III questionnaire are presented in Figure 34, and demonstrate that the 
IMPACT-III total HRQOL score was negatively correlated with the HADS total anxiety 
score. Similarly, the data in Figure 35 illustrate that the IMPACT-III total HRQOL score 
was negatively correlated with the HADS total depression score. 
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Data analyzed from 41 patients and families who completed both the PIP 
Frequency column and the SCARED are presented in Figure 36, and demonstrate that the 
SCARED total anxiety score is positively correlated with the PIP total frequency score. 
Similarly, the data from 38 patients and families who completed both the PIP Difficulty 
column and the SCARED are illustrated in Figure 37 and demonstrate a positive 
correlation between the SCARED total anxiety and PIP total difficulty scores. 
Data analyzed from 41 patients and families who completed both the PIP 
Frequency column and the PHQ-9 are illustrated in Figure 38 and illustrate a positive 
correlation between the PHQ-9 total depression and PIP total frequency scores. Similarly, 
data from 38 patients and families who completed both the PIP Difficulty column and the 
PHQ-9 illustrate a positive correlation between the PHQ-9 total depression score and the 
PIP total difficulty score (Figure 39). 
Data analyzed from 42 patients and families who completed both the PIP 
Frequency column and the IMPACT-III questionnaire is presented in Figure 40 and 
illustrate a negative correlation between the IMPACT-III total HRQOL and PIP total 
frequency scores. Similarly, data from 39 patients and families who completed both the 
PIP Difficulty column and the IMPACT-III questionnaire illustrate a negative correlation 
between the IMPACT-III total HRQOL score and the PIP total difficulty score (Figure 
41). 
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Figure 32. Impact of Parental Anxiety on Child Anxiety. This figure shows the 
relationship between the HADS total anxiety score and the SCARED total anxiety score. 
Data were analyzed from 45 patient/parent dyads who completed both questionnaires. 
 
 
Figure 33. Impact of Parental Depression on Child Depression. This figure shows the 
relationship between the HADS total depression score and the PHQ-9 total depression 
score. Data were analyzed from 44 patient/parent dyads who completed both measures. 
0
10
20
30
40
50
60
0 5 10 15 20 25Ch
ild	SCA
RED	To
tal	Anx
iety	Sco
re
Parent	HADS	Total	Anxiety	Score
Impact	of	Parental	Anxiety	on	Child	Anxiety
02
46
810
1214
16
0 2 4 6 8 10 12 14 16 18 20Chil
d	PHQ-
9	Total
	Depre
ssion	S
core
Parent	HADS	Total	Depression	Score
Impact	of	Parental	Depression	on	Child	Depression
 75 
 
Figure 34. Impact of Parental Anxiety on Child Quality of Life. This figure shows the 
relationship between the HADS total anxiety score and the IMPACT-III total HRQOL 
score. Data were analyzed from 45 patient/parent dyads who completed both measures. 
 
 
Figure 35. Impact of Parental Depression on Child Quality of Life. This figure shows 
the relationship between the HADS total depression score and the IMPACT-III total 
HRQOL score. Data were analyzed from 45 patient/parent dyads who completed both 
measures. 
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Figure 36. Impact of Frequent Parental Stress on Child Anxiety. This figure shows 
the relationship between the PIP total frequency score and the SCARED total anxiety 
score. Data were analyzed from 41 patient/parent dyads who completed both measures. 
 
 
Figure 37. Impact of Difficult Parental Stress on Child Anxiety. This figure shows the 
relationship between the PIP total difficulty score and the SCARED total anxiety score. 
Data were analyzed from 38 patient/parent dyads who completed both measures. 
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Figure 38. Impact of Frequent Parental Stress on Child Depression. This figure 
shows the relationship between the PIP total frequency score and the PHQ-9 total 
depression score. Data were analyzed from 41 patient/parent dyads who completed both 
measures. 
 
 
Figure 39. Impact of Difficult Parental Stress on Child Depression. This figure shows 
the relationship between the PIP total difficulty score and the PHQ-9 total depression 
score. Data were analyzed from 38 patient/parent dyads who completed both measures. 
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Figure 40. Impact of Frequent Parental Stress on Child Quality of Life. This figure 
shows the relationship between the PIP total frequency score and the IMPACT-III total 
HRQOL score. Data were analyzed from 42 patient/parent dyads who completed both 
measures. 
 
 
Figure 41. Impact of Difficult Parental Stress on Child Quality of Life. This figure 
shows the relationship between the PIP total difficulty score and the IMPACT-III total 
HRQOL score. Data were analyzed from 39 patient/parent dyads who completed both 
measures. 
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DISCUSSION 
 
 Analysis of the data on the study’s patient population reveals consistency with 
previous studies and academic literature on pediatric IBD. With 41 patients diagnosed 
with CD and 28 with UC, the higher incidence rate of CD than UC is consistent with 
most epidemiological studies on pediatric IBD from the last decade (Malmborg & 
Hildebrand, 2015). The CD population is distributed 23 to 18 between males and females, 
which reflects the male preponderance in pediatric CD. On the other hand, the UC 
population is divided 15 to 13 between males and females, which indicates the tendency 
of UC to affect both sexes equally (Kapoor, Bhatia, & Sibal, 2016). Furthermore, the 
mean age on the date of consent was about 14½ years old for both males and females. 
Because the study is designed to enroll patients who have been diagnosed with IBD 
within the previous six months, it can be deduced that the mean age on the date of 
diagnosis was about 14 years old. This too is consistent with findings that peak onset of 
pediatric IBD occurs in adolescence (Keethy, Mrakotsky, & Szigethy, 2014; Rosen, 
Dhawan, & Saeed, 2015). 
 The data on the patient population also reveals some of the study’s limitations and 
difficulties in the data collection process. Most notably, the number of patients and 
families who have not completed their baseline or follow-up questionnaires demonstrates 
the difficulty in maintaining communication and relying on them to participate. Patients 
and families who have not completed their baseline questionnaires are most often the 
ones who opted to either take the paper questionnaires home and return them through the 
mail or receive the digital link via email to complete the questionnaires electronically. 
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This comes as no surprise – when patients and families take the paper questionnaires 
home, it is easy for them to lose the papers, forget to complete them, have them get lost 
in the mail upon return, or simply withdraw from the study without communicating with 
the research team. Similarly, when patients and families choose to receive the digital link 
via email, it is easy for them to forget about the email or simply ignore it. This also can 
explain the lack of success in retaining patients at one-year follow-up, given that most of 
them are approached for the follow-up encounter via email. 
The data collected from the baseline patient study measures are also consistent 
with previous findings and current literature on pediatric IBD. Numerous studies have 
found that anxiety and depression are more prevalent in IBD than in healthy or disease 
controls (Byrne et al., 2017; Goodhand et al., 2012; McCombie, Mulder, & Gearry, 2015; 
Rosen, Dhawan, & Saeed, 2015) and that IBD adversely affects the patient’s quality of 
life (Fuller-Thomson, Lateef, & Sulman, 2015; Rabizadeh & Dubinsky, 2013). Figure 12 
and Table 4 indicate that the mean standardized T-scores from the CDI data represent a 
typical number of concerns and are considered average scores. Moreover, Table 5 
indicates that the mean scores calculated from the IMPACT-III questionnaire data are 
considered above average and thus represent an above-average quality of life. It is 
important to remember that these are mean values and that not all youth with IBD have 
depression or low quality of life. Despite what these results may suggest, the study 
population does in fact contain patients who strongly indicate for anxiety, depression, 
and/or low quality of life. 
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This is much more evident in the analysis of the other two baseline patient study 
measures. Figure 13 illustrates the data accumulated from the SCARED and shows that 
about 43% of the study population reported low scores that did not qualify for any 
anxiety disorder or symptoms, meaning that the remaining 57% met criteria for indication 
of at least one type of anxiety disorder. Furthermore, Figure 14 shows that from the data 
gathered from the PHQ-9, 30% of patients indicated for mild depression and 13% 
indicated for moderate depression. These findings reinforce the association of IBD with 
anxiety and depression and suggest that screening for both conditions in the pediatric 
IBD population would be of value (Byrne et al., 2017). 
Although the role of parents in the pediatric IBD population has not been 
thoroughly examined (Gray et al., 2013; Guilfoyle et. al, 2012), the data collected from 
the baseline parent study measures aligned with the expectations of the study team. 
Figure 15 illustrates that among the different types of healthcare resource utilization, 
phone calls with the child’s pediatrician and GI doctor were most common, followed by 
office visits, ER visits, and inpatient hospitalizations. This order makes sense, given that 
phone calls are easiest and require the least investment of time and money, whereas ER 
visits and hospitalizations are difficult and more expensive and time consuming. Table 6 
indicates that the mean frequency and difficulty scores from the PIP data are considered 
below average and thus represent below average levels of stress. Much like with the CDI 
and the IMPACT-III, it should be noted that these are mean values and that the study 
population does have parents with high stress levels. Further analysis is needed to explain 
the tendency of the mean frequency score to be greater than the mean difficulty score. 
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The HADS was unique in that it was able to simultaneously assess for levels of 
anxiety and depression. Studies have yet to establish whether parents of children with 
newly diagnosed IBD are more likely to experience anxiety or depression. However, the 
study team hypothesized that these parents would more likely exhibit anxiety symptoms, 
based on anxiety being more common and pervasive than depression (“Understand the 
Facts”, n.d.). Figure 16 illustrates that the parents displayed a higher mean total anxiety 
score (6.87) than mean total depression score (4) on the HADS. Furthermore, Figure 17 
demonstrates that 22% of the parents indicated for borderline abnormal anxiety and 23% 
indicated for abnormal anxiety. In contrast, that same population of parents only saw 4% 
indicate for borderline abnormal depression and 12% indicate for abnormal depression, as 
seen in Figure 18. These findings suggest that the study team’s hypothesis was correct. 
 As stated earlier, little is known about the stability of coping strategies and how 
they change over time because of the dearth of longitudinal studies on coping in IBD 
(McCombie, Mulder, & Gearry, 2015). Therefore, one of the specific aims of this study 
was to assess the stability of coping measures over time in children and parents following 
a new pediatric IBD diagnosis. Figures 19-27 show the changes between the calculated 
total scores at baseline and follow-up for each study measure. Some questionnaires saw 
all of its patients show the same kind of change from baseline to follow-up, while other 
questionnaires displayed more mixed results. Because of the small sample size of study 
participants who have completed the questionnaires at both baseline and follow-up, no 
definitive conclusions can be drawn from these results just yet. Further analysis will 
require more patients and families to continue with the study at their follow-up encounter. 
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 Another area of pediatric IBD that has not yet been fully investigated is its effects 
on healthcare resource utilization. Thus, the study also aimed to assess the impact of 
parental coping on parental healthcare resource utilization for children with newly 
diagnosed IBD. The study team hypothesized that poor parental coping would correlate 
with increased healthcare utilization. Figures 28-31 examine this relationship using data 
collected from the baseline parent study measures. The figures suggest that parental 
anxiety, parental depression, frequent parental stress, and difficult parental stress are all 
positively correlated with the total number of healthcare utilization instances. These 
findings support the study team’s hypothesis and seem logical – it makes sense that 
parents who are more anxious, depressed, and stressed regarding their child’s new IBD 
diagnosis would be more likely to make phone calls and office visits to their child’s 
pediatrician and GI doctor. Like any correlation, it is possible that this relationship may 
be caused by other variables that are closely related to both parental coping and 
healthcare utilization, so further analysis should attempt to assess whether or not this 
association is significant.  
 The final aim of the study was to assess the impact of parental coping on anxiety, 
depression, and quality of life in children with newly diagnosed IBD. The study team 
hypothesized that children with newly diagnosed IBD who operate within families that 
display maladaptive coping strategies would demonstrate higher anxiety and depression 
and lower quality of life. Using total scores calculated from the HADS, PIP, SCARED, 
IMPACT-III questionnaire, and PHQ-9, Figures 32-41 illustrate various relationships 
between the parent study measures and patient study measures. 
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One major finding from these results was that parental anxiety, parental 
depression, frequent parental stress, and difficult parental stress were all negatively 
correlated with the child’s HRQOL. These results not only support the study team’s 
hypothesis, but are also consistent with pediatric IBD literature. Poor family functioning 
is linked with poorer child HRQOL (Gray et al., 2013). Furthermore, if the family utilizes 
ineffective or maladaptive coping mechanisms, there is a negative impact on HRQOL 
(Bishop, Lemberg, & Day, 2014).  
Another significant finding was that parental anxiety, frequent parental stress, and 
difficult parental stress were all positively correlated with the child’s anxiety. Similarly, 
parental depression, frequent parental stress, and difficult parental stress were all found to 
be positively correlated with the child’s depression. These results also support the study 
team’s hypothesis and are consistent with previous findings, which have linked parenting 
stress with adolescent depressive symptoms in a smaller pediatric IBD sample (Gray et 
al., 2013). Additionally, it has been suggested that young people with IBD often rely on 
their parents’ abilities to cope (MacPhee, Hoffenberg, & Feranchak, 1998; Bishop, 
Lemberg, & Day, 2014), so it is understandable that higher levels of parental anxiety, 
depression, and stress could lead to higher levels of child anxiety and depression. As 
mentioned earlier, numerous studies have found that anxiety and depression are more 
prevalent in IBD than in healthy or disease controls (Byrne et al., 2017; Goodhand et al., 
2012; McCombie, Mulder, & Gearry, 2015; Rosen, Dhawan, & Saeed, 2015). These 
findings suggest that maladaptive parental coping strategies could be a major reason why. 
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 As alluded to earlier, the breadth and accuracy of these results are somewhat 
hindered by the study’s limitations and difficulties in the process of collecting data. The 
challenge of getting patients and parents to complete their baseline or follow-up 
questionnaires has already been discussed. For those that do participate in the study at 
both time points, the follow-up encounter may not be exactly one year from their date of 
consent; it could range anywhere between 10 to 18 months from that date. In addition, 
because the study participants do not need to answer every item on the administered 
questionnaires, partial completion can lead to significant amounts of missing data. This 
affects both the number of participants included in the data analysis and the accuracy of 
the calculations in each study measure. Patients and parents may provide inaccurate 
responses on their own as well. Their answers may be conservative or exaggerated 
because of embarrassment or social desirability. They might also answer questions based 
on what they believe the answer should be or what they believe the research team wants 
to hear. 
 The results from this study provide a better understanding of how families cope 
with pediatric IBD and how it impacts both children/adolescents and their parents. They 
also demonstrate that there is a need to develop better ways to support these families in 
the future. Overall, these findings are part of many preliminary steps toward the 
development of therapies and programs that will be aimed at helping families with a child 
who is newly diagnosed with a chronic illness like IBD.   
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CONCLUSION 
 This prospective, longitudinal cohort study focused on children and adolescents 
with newly diagnosed IBD, as well as their parents. The study was aimed at assessing the 
stability of coping measures over the first year of the diagnosis and the impact of parental 
coping on healthcare utilization and the child’s anxiety, depression, and quality of life. 
Preliminary findings suggest that poor parental coping leads to decreased child quality of 
life and increased healthcare utilization, child anxiety, and child depression. Definitive 
conclusions have yet to be deduced regarding the stability of coping measures over time. 
 The next steps for the study involve further examination of the impact of parental 
coping and enrollment of more patients and families. The research team would like to 
assess the impact of parental coping on disease activity, as measured by PUCAI and 
PCDAI scores, in children with newly diagnosed IBD. There are also plans to make it a 
multi-center study by enrolling patients and collecting data from other IBD centers, such 
as Massachusetts General Hospital. This will not only increase the study’s enrollment but 
also will generalize the findings to the pediatric IBD population at large. 
 The primary goals of this study overall are to identify those patients and families 
most in need of assistance and to use the information collected in the study to develop 
appropriate medical psychosocial supports to meet their needs. In the long-run, the 
research team hopes to improve quality of care and reduce overall medical utilization. By 
having a better understanding of how the coping strategies exercised by children and their 
families impact clinical management, disease outcome, and emotional well-being in 
children with a new IBD diagnosis, the team believes that it can accomplish these goals. 
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